6020-61-7

Usage

Uses

Used in Organic Synthesis:
(2E)-3-(4-fluorophenyl)-1-(3-methoxyphenyl)prop-2-en-1-one is used as a building block in organic synthesis for the creation of various pharmaceuticals and biologically active molecules. Its unique structural elements contribute to the development of complex organic compounds.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, (2E)-3-(4-fluorophenyl)-1-(3-methoxyphenyl)prop-2-en-1-one serves as an important intermediate. It aids in the production of drugs and other bioactive compounds, thanks to its distinctive properties that are beneficial for medicinal applications.
Used in Pharmaceutical Sciences:
(2E)-3-(4-fluorophenyl)-1-(3-methoxyphenyl)prop-2-en-1-one is utilized as a useful tool in pharmaceutical sciences. Researchers leverage its unique properties to advance their work, making it an essential component in the discovery and development of new drugs and therapies.

Upstream product

• 521-04-0 24β_F-ethyl-cholestadien-(5.7)-ol-(3β) 
• 108-24-7 acetic anhydride 
• 128-08-5 N-Bromosuccinimide 
• 60-29-7 diethyl ether 
• 915-05-9 stigmast-5-en-3-yl acetate 
• 521-04-0 stigmastadien-(5.7)-ol-(3β) 
• 54200-16-7 Acetic acid (3S,8S,9S,10R,13R,14S,17R)-7-bromo-17-((1R,4R)-4-ethyl-1,5-dimethyl-hexyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl ester 
• 83-46-5 β-sitosterol 
• 59157-68-5 3β,7β-dibenzoyloxy-stigmastene-(5) 
• 4863-54-1 5-stigmasten-3β,7β-diol 

Downstream Products

• 71761-06-3 9,10-seco-stigmasta-5(Z),7(E),10(19)-trien-3β-ol 
• 865539-87-3 9,10-seco-stigmasta-5(E),7(E),10(19)-trien-3β-ol 
• 865539-85-1 Acetic acid (S)-3-[2-[(1R,3aS,7aR)-1-((1R,4R)-4-ethyl-1,5-dimethyl-hexyl)-7a-methyl-octahydro-inden-(4E)-ylidene]-eth-(Z)-ylidene]-4-methylene-cyclohexyl ester 
• 865539-88-4 3β-triethylsilyloxy-9,10-seco-stigmasta-5(E),7(E),10(19)-triene 
• 521-04-0 Δ⁵-stigmasterol 

Relevant academic research and scientific papers

Synthesis and biological activity evaluation of novel peroxo-bridged derivatives as potential anti-hepatitis B virus agents

Previous studies have demonstrated that natural steroid compounds containing a peroxide bridge exhibited potential anti-hepatitis B virus activity. To continue our research, a simple and regioselective methodology, using Eosin Y as a clean photosensitized oxidation catalyst, was developed for the synthesis of a peroxide bridge in steroids. The method that using Eosin Y as the catalyst was exposed to visible light and furbished in high yields, did not involve tedious work-up or purification, and avoided using environmentally hazardous solvents. It can be regarded as a green protocol. Moreover, a series of cholesterol and β-sitosterol derivatives containing a peroxide bridge were synthesized using this method and screened for their anti-HBV activity. Among the compounds synthesized in this research, 5α,8α-cyclicobioxygen-6-vinyl-3-oxo-cholesterone (1f, 3.13 μg ml?1) had the most potent activity with inhibition rates of 77.45% ± 6.01% and 58.73% ± 8.64% on the secretion of HBsAg and HBeAg antigens, respectively, after 8 days. Further acute toxicity test showed that the LD50 value of compound 1f was 362.46 mg kg?1 after an intraperitoneal injection in mice. Moreover, structure-activity relationships of cholesterol and β-sitosterol derivatives were briefly discussed.

Synthesis of 1α-Hydroxyvitamin D5 using a modified two wavelength photolysis for vitamin D formation

1α-Hydroxyvitamin D5 (1) is a promising chemopreventive agent for breast cancer and is being developed as a drug. We report a synthesis for this vitamin D analogue which uses a photochemical method for the B-ring opening, leading to the conjugated triene system. The precursor 7-dehydrositosteryl acetate (4) obtained through a one-pot, five-step procedure, was completely free of the 4,6-diene isomer that usually forms in the 5,7-diene synthesis. The pre-vitamin isomer (11) was generated using a modified two-wavelength photolysis procedure that increases the yield for this step more than 3-fold compared to classically used photolysis. The 1α-hydroxylation step was performed on the 3-triethylsilyl-trans-vitamin D5 (17) obtained via the sulfur dioxide adduct of cis-vitamin D5, in an overall yield of 48%. Photoisomerization and deprotection completed the synthesis.